阿托伐他汀对人类精液和性腺激素的影响
他汀类药物引起的胆固醇水平降低对精子质量的影响
Recently, concerns about the effect of atorvastatin intake on men fertility have been raised. However, this statin has never been investigated regarding its influence on male fertility, notably sperm quality.
The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
研究概览
详细说明
The main objective is to estimate the safety of atorvastatin on fertility of normocholesterolaemic and healthy men (having normal blood lipid profile and normal sperm parameters) by analyzing its effects on sperm parameters: ejaculate volume, sperm count, total and progressive motility, percentage of typical forms.
The secondary objectives are to assess the changes in:
- hormonal profile: gonadotropins and testosterone plasma levels
- lipid composition of sperm and seminal fluid;
- spermatozoa capacitation markers
- accessory glands markers.
The efficacy is estimated by measuring the lipid lowering action of atorvastatin. It is expected a decrease by 20 and 40% of total cholesterol blood and LDL-cholesterol levels, respectively (total cholesterol <1.5 g / l and LDL-cholesterol <1g / l).
Considering this protocol as a pilot study to evaluate safety and efficacy, sample size estimation was fixed considering a Fleming design at one stage. These designs with one group and multi-stages (between 1 and 5) can be seen as filtering steps leading to the decision type go/no go. With a type I error a and statistical power (1-β) equals respectively 5% and 90%, n=17 subjects were necessary to reject the hypotheses of minimal (p=0.85) and maximal (p=0.95) acceptable non-toxicity. If 1 subject or more presented a toxicity, the treatment was considered no safe. To measure the evolution of total cholesterol and LDL-cholesterol levels concerning the efficacy, n=17 subjects were necessary to show a minimal paired difference (to be detected) of 0.5 with expected standard-deviation of difference = 0.5, correlation coefficient of 0.5, a= 5% (two-sided) for a power greater than 90% (1-β=97%).
Subjects are included after a screening visit (visit 0), during which routine laboratory biochemical tests are performed, an electrocardiogram is taken, blood pressure, weight and height are measured; physical examination including testis evaluation and semen parameters are analyzed according to WHO standards 1999 .
The subjects take atorvastatin orally (10mg/day (d), Tahor©, Pfizer Laboratory) during 5 months allowing to study atorvastatin effects on human spermatogenesis and epididymal maturation (one cycle requiring approximately 3 months).
Blood and semen parameters were measured :
- before to take atorvastatin treatment (visit 1)
- at the end of the therapy (visit 3)
- and 3 months after the end of treatment, (visit 4) to perform measurements during different cycles of spermatogenesis on a same subject. After two months of treatment, a consultation (visit 2) is realized to ensure good tolerance to treatment and to control treatment efficiency.
Biochemical clinical and semen measurements take before treatment were considered as "control baseline measures".
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Clermont-Ferrand、法国、63003
- CHU de Clermont-Ferrand
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Men :
- between 18 and 65 years ;
- with normal conventional semen parameters and negative semen culture according to WHO standards 1999 : volume ejaculate ≥ 2 ml, sperm count ≥ 20millions/ml, total motility ≥ 50% progressive motility ≥ 30%, typical forms ≥ 20%;
- with normal blood lipid profile: total cholesterol < 2.50g/L, triglycerides < 1.70g/L, HDL-C > 0.35 g/L and LDL-C < 2.2 g/L;
- without known pathology or ongoing treatment
Exclusion Criteria:
- Subjects with medical or surgical history that may make them at risk during the study,
- Subjects with cons-indications to taking atorvastatin
- Subjects with an active liver disease or increased level of serum transaminases
- Subjects with a history of allergy
- Subjects whose lipid parameters do not match the inclusions criteria or receiving lipid-lowering therapy
- Subject with abnormal semen analysis or cryptorchidism or a varicocele
- Subjects who participated in another clinical trial or other experimentation or other tolerance study of a drug
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:阿托伐他汀
|
The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
阿托伐他汀治疗 5 个月后对精液质量所有变化的观察
大体时间:第 5 个月
|
第 5 个月
|
|
阿托伐他汀治疗 5 个月后和停药 3 个月后对精液质量所有变化的观察
大体时间:第 8 个月
|
第 8 个月
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
hormonal profile: gonadotropins and total testosterone plasma levels
大体时间:at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
lipid composition of sperm and seminal fluid
大体时间:at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
spermatozoa capacitation markers
大体时间:at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
|
accessory glands markers
大体时间:at month 5
|
All modifications observed after 5 months of atorvastatin therapy and after 3 months after the end of treatment on |
at month 5
|
合作者和调查者
合作者
调查人员
- 首席研究员:Igor TAUVERON、University Hospital, Clermont-Ferrand
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.